Relay Therapeutics Is A Clinical Stageprecision Medicines Company Based In Cambridgemassachusettsfounded In 2016Thecompany Specializes In Drug Discovery By Integrating Computational And Experimental Technologiesits Proprietary Dynamo Platform Combines Advanced Experimental Techniquessuch As Cryo Em And X Ray Crystallographywith Molecular Dynamics Simulations To Analyzeprotein Motionthis Innovativeapproach Aims To Identify Drug Candidates That Target Diseaserelevant Protein Dynamicsparticularly In Oncology And Genetic Diseases Thecompany Has Developed Several Clinical Stagecandidatesincluding Rly 4008A Selectivefgfr2 Inhibitorand Rly 2608Which Targets Pi Kimutations In Solid Tumorsrelay Therapeutics Has Established Strategic Partnershipsnotably With Genentechto Enhanceits Drug Discovery Effortsthecompany Went Public In 2020Raising Over $400 Million To Support Theclinical Advancement Of Its Programsrelay Therapeutics Is Committed To Addressing Unmet Needs In Precision Medicineby Leveraging Insights From Protein Dynamics
